CII
ANGO icon

CR Intrinsic Investors’s AngioDynamics ANGO Stock Holding History

CR Intrinsic Investors’s Portfolio ANGO Stock Details ANGO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-115,000
Closed -$1.98M – 264
2013
Q4 		$1.98M Buy
+115,000
New +$1.77M 0.09% 239

Other funds holding ANGO

RC
RGM Capital Naples, Florida $2.06B AUM 8.49% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SFM
Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LAM
Lapides Asset Management Greenwich, Connecticut $153M AUM 9.03% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TAM
THB Asset Management Norwalk, Connecticut $440M AUM 59.59% 1-Year Est. Return

CR Intrinsic Investors's ANGO Position: Q1 2014 in Review

CR Intrinsic Investors sold out of AngioDynamics (ANGO) in Q1 2014, closing a stake of 115,000 shares — an estimated $1.98M sold.

CR Intrinsic Investors first reported a position in ANGO in Q4 2013 and held it in 1 quarter. The position peaked at $1.98M in Q4 2013. 109 funds tracked by Wall St. Rank hold ANGO as of Q1 2014.

  • CR Intrinsic Investors reported no remaining AngioDynamics position as of Q1 2014 after selling out during the quarter.
  • CR Intrinsic Investors sold 115,000 AngioDynamics shares in Q1 2014, an estimated $1.98M.
  • CR Intrinsic Investors first reported a position in AngioDynamics in Q4 2013 and held it in 1 quarter.
  • CR Intrinsic Investors's AngioDynamics position peaked at $1.98M in Q4 2013.
  • 109 funds tracked by Wall St. Rank held AngioDynamics as of Q1 2014.

Based on CR Intrinsic Investors's 13F filing for Q1 2014, filed 15 May 2014.